With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Creative Planning raised its stake in GSK by 3.9% in the third quarter. Creative Planning now owns 211,100 shares of the pharmaceutical company’s stock worth $8,630,000 after buying an ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Atria Investments Inc cut its holdings in GSK plc (NYSE:GSK – Free Report) by 7.6% in the fourth quarter, according to the ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

Full Year 2024 Results Key Financial Results Revenue: UK£31.4b (up 3.5% from FY 2023). Net ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...